Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
Why MIRA Pharmaceuticals is targeting chemotherapy-induced nerve pain with Ketamir-2
Find out how MIRA Pharmaceuticals aims to transform CIPN care with Ketamir-2 and why regulators and investors are watching its 2026 development milestones.